MX2012002977A - (heteroarilmetil)tiohidantoinas sustituidas como drogas anticancer. - Google Patents

(heteroarilmetil)tiohidantoinas sustituidas como drogas anticancer.

Info

Publication number
MX2012002977A
MX2012002977A MX2012002977A MX2012002977A MX2012002977A MX 2012002977 A MX2012002977 A MX 2012002977A MX 2012002977 A MX2012002977 A MX 2012002977A MX 2012002977 A MX2012002977 A MX 2012002977A MX 2012002977 A MX2012002977 A MX 2012002977A
Authority
MX
Mexico
Prior art keywords
heteroarylmethyl
thiohydantoins
sustituted
anticancer drugs
prophylaxis
Prior art date
Application number
MX2012002977A
Other languages
English (en)
Spanish (es)
Inventor
Arwed Cleve
Bernard Haendler
Silke Koehr
Ulrich Luecking
Hortensia Faus Gimenez
Horst Irlbacher
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2012002977A publication Critical patent/MX2012002977A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2012002977A 2009-09-11 2010-08-28 (heteroarilmetil)tiohidantoinas sustituidas como drogas anticancer. MX2012002977A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075421 2009-09-11
EP10075069 2010-02-17
PCT/EP2010/005297 WO2011029537A1 (en) 2009-09-11 2010-08-28 Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs

Publications (1)

Publication Number Publication Date
MX2012002977A true MX2012002977A (es) 2012-04-30

Family

ID=42782041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002977A MX2012002977A (es) 2009-09-11 2010-08-28 (heteroarilmetil)tiohidantoinas sustituidas como drogas anticancer.

Country Status (28)

Country Link
US (1) US20120251551A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2475653A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2013504523A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20120065396A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN102639523A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR078166A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2010294588A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112012005526A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2773591A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2012000623A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO6511228A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20120113A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CU (1) CU20120042A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2012000063A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA201200473A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP12011716A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL218390A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2012DN02081A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA33566B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2012002977A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ598643A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20121180A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12012500497A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG178919A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TN2012000108A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW201111378A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY32882A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2011029537A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20130184A1 (es) 2010-02-17 2013-03-09 Takeda Pharmaceutical Compuesto heterociclico
EP2576536B1 (en) * 2010-06-01 2016-09-14 The University of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
EA035493B1 (ru) 2011-12-22 2020-06-25 Янссен Байофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HUE029038T2 (en) 2012-05-25 2017-01-30 Janssen Sciences Ireland Uc Uracil spirooxetan nucleosides
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
KR102532198B1 (ko) 2012-12-21 2023-05-11 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN104341351B (zh) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 一种二芳基硫代乙内酰脲衍生物及其应用
JP6430512B2 (ja) * 2013-12-11 2018-11-28 セルジーン クオンティセル リサーチ,インク. リジン特異的デメチラーゼ−1の阻害剤
EP3083596A1 (en) 2013-12-18 2016-10-26 Basf Se Azole compounds carrying an imine-derived substituent
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
AU2015257917C1 (en) 2014-05-07 2019-03-14 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
ES2819869T3 (es) 2015-10-08 2021-04-19 Bayer Pharma AG Nuevos compuestos macrocíclicos modificados
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CA3057892A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
EP3625215B1 (en) 2017-05-18 2023-09-13 PI Industries Ltd Formimidamidine compounds useful against phytopathogenic microorganisms
CA3090843A1 (en) 2018-02-13 2019-08-22 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma
MX2021012499A (es) * 2019-04-11 2022-01-24 Univ Miami Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
AU2021209875A1 (en) * 2020-01-21 2022-08-11 Georgia Tech Research Corporation Aryl hydantoin heterocycles and methods of use
CN117120436A (zh) * 2021-03-30 2023-11-24 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法
WO2025103470A1 (zh) * 2023-11-17 2025-05-22 中国药科大学 作为雄激素受体(ar)拮抗剂的化合物及其应用
CN120309588B (zh) * 2025-06-10 2025-08-12 上海健康医学院 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
DE69938005T2 (de) 1998-09-22 2009-01-15 Astellas Pharma Inc. Cyanophenyl-derivate
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
WO2003087061A1 (en) 2002-04-12 2003-10-23 Pfizer Japan Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
WO2005005399A1 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Oxazolidinone antibiotics and derivatives thereof
CA2540704A1 (en) 2003-09-30 2005-05-19 Janssen Pharmaceutica N.V. Benzoimidazole compounds
MXPA06007326A (es) 2003-12-23 2007-01-26 Astex Therapeutics Ltd Derivados de pirazol como moduladores de proteina cinasa.
TW200612920A (en) 2004-08-03 2006-05-01 Chugai Pharmaceutical Co Ltd Novel imidazolidine derivatives
US8470829B2 (en) 2004-09-09 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Imidazolidine derivative and use thereof
CN101068786A (zh) 2004-12-03 2007-11-07 霍夫曼-拉罗奇有限公司 作为h3拮抗剂的3-取代的吡啶衍生物
NZ591119A (en) * 2005-05-13 2012-08-31 Univ California Use of diarylhydantoin compounds for treating specific cancers
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
MX2008012492A (es) 2006-03-29 2008-12-12 Univ California Compuestos de diariltiohidantoina.
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Also Published As

Publication number Publication date
PH12012500497A1 (en) 2012-10-22
CU20120042A7 (es) 2012-06-21
MA33566B1 (fr) 2012-09-01
KR20120065396A (ko) 2012-06-20
NZ598643A (en) 2013-10-25
IN2012DN02081A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-08-21
US20120251551A1 (en) 2012-10-04
IL218390A0 (en) 2012-04-30
UY32882A (es) 2011-04-29
CA2773591A1 (en) 2011-03-17
CN102639523A (zh) 2012-08-15
BR112012005526A2 (pt) 2016-04-26
CR20120113A (es) 2012-05-02
JP2013504523A (ja) 2013-02-07
AR078166A1 (es) 2011-10-19
CL2012000623A1 (es) 2012-09-14
DOP2012000063A (es) 2012-05-15
WO2011029537A1 (en) 2011-03-17
SG178919A1 (en) 2012-04-27
EA201200473A1 (ru) 2012-10-30
CO6511228A2 (es) 2012-08-31
ECSP12011716A (es) 2012-04-30
PE20121180A1 (es) 2012-08-24
TN2012000108A1 (en) 2013-09-19
AU2010294588A1 (en) 2012-04-05
TW201111378A (en) 2011-04-01
EP2475653A1 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
TN2012000108A1 (en) Sustituted (heteroarylmethyl) thiohydantoins as anticancer drugs
PH12014500867A1 (en) Anticancer pyridopyrazines via the inhibition of fgfr kinases
MX2014004861A (es) Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
PH12012501993A1 (en) Pyrazolyl quinazoline kinase ihibitors
CA2871471C (en) Dna-pk inhibitors
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MX2015006152A (es) Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.
MX346147B (es) Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
PH12012501337A1 (en) Substituted pyrrolo-aminopyrimidine compounds
MX366899B (es) Nuevos compuestos.
MX2012003851A (es) Tratamiento de cánceres resistentes antagonistas notch1, mediante el uso de antagonistas notch3.
IN2012DN02471A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH12012501556A1 (en) Substituted naphthalenyl-pyrimidine compounds
CA2865983A1 (en) Potent anticancer activity via dual compound activation
MX2011006532A (es) Compuestos anticancerigenos.
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer
MX2012007471A (es) Compuestos substituidos de pirrolo-aminopirimidina.

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights